[Acipimox treatment of hyperlipidemia type II].
The hypolipidemic effect of acipimox, a new inhibitor of lipolysis, was investigated in a double blind crossover trial versus placebo. The trial showed an appreciable and significant reduction in total cholesterol (-14%) and of LDL cholesterol (-20%), a slight but significant increase in HDL cholesterol (+6%), and only a slight diminution of triglycerides and VLDL cholesterol.